Latest Regulatory News

Lake Resources N.L. has scheduled an Extraordinary General Meeting on 7 October 2025 to seek shareholder approval for the second tranche of its $12 million placement and the issuance of new options to investors and directors.

Marimaca Copper has raised A$80 million through a brokered placement to fund detailed engineering and exploration at its flagship Chilean projects, signaling strong investor confidence.

Austral Resources Australia Ltd has secured an extension of its ASX suspension to 31 October 2025, enabling the company to finalize the pivotal Rocklands transaction and associated capital raise.

EMU NL has announced a $1.83 million non-renounceable entitlement offer to fund exploration at its Georgetown and Badja projects, while facing potential board upheaval at an upcoming general meeting.

Simble Solutions has exited its digital asset holdings, selling all Bittensor tokens at a slight loss following new ASX guidance. The company signals a strategic pivot away from digital assets in its treasury management.

Xamble Group Limited’s XGLO securities have been suspended from trading pending compliance with ASX listing rules, raising questions about the company’s regulatory standing.

Rubix Resources (ASX, RB6) has resumed trading after lifting its suspension, following key announcements on its drilling program, capital raising, and a proposed acquisition.

Rubix Resources has entered a non-binding agreement to acquire bauxite exploration projects in Cameroon and Congo, with a structured payment plan including cash, shares, and performance rights tied to resource milestones.

Diablo Resources has secured key drilling approvals for its Phoenix Copper Project in Utah, accelerating exploration in a critical US copper district. Early surface samples at the Fair Dinkum Prospect show promising copper and silver grades, setting the stage for a pivotal drilling campaign.

Bannerman Energy has locked in two binding offtake agreements with major North American utilities for 1 million pounds of uranium from its Etango project, marking a significant milestone ahead of its final investment decision.

PYC Therapeutics has completed dosing in its Phase 1 study of PYC-001 for Autosomal Dominant Optic Atrophy, showing strong safety and early signs of improved vision. The company plans to launch a global Phase 1/2 trial later this year.

SiteMinder Limited has confirmed its FY25 financial results aligned closely with market expectations and analyst forecasts, explaining the recent share price surge following its earnings release.